Dover has entered into a definitive agreement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
เกจวัดแรงดันไฟฟ้า will expand Dover’s biopharma single-use production providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue through the full 12 months 2022.
When the deal closes, Malema will become a half of the PSG business unit within Dover’s Pumps & Process Solutions phase.
“We see an amazing long-term growth opportunity within the bioprocessing industry driven by a strong and growing pipeline of efficient novel biologic medicine, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of extra efficient single-use manufacturing processes supports a robust outlook for our choices of single-use parts to end-customers. We consider that pairing Malema’s technology with our present portfolio of single-use pumps for biopharma processing will significantly improve the accuracy and value proposition of our options to our clients.”
“We are methodically constructing out our biopharma platform via proactive capacity additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest element technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and additional strengthens our sensor portfolio with new proprietary know-how. In addition to enticing biopharma functions, we count on strong development in the semiconductor area on the capacity growth and re-shoring tailwinds.”
Share